Symlin
(pramlintide)ApprovedPeptide
AstraZenecaSymlin is one of 206 small molecule programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Approved.
7
Indications
15
Total Trials
1
Active Trials
205
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaApproved
Byetta
AstraZenecaPreclinical
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Golytely
BayerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 1 Diabetes4 trials
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06046417·30 enrolled
Show 1 more trial
Hyperglycemia2 trials
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Completed·—·Phase 4·NCT01269047·37 enrolled
Hypoglycemia1 trial
Diabetes Mellitus1 trial
6 more indications
Pediatric1 trial
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
Completed·—·Phase 3·NCT00206297·20 enrolled
Type 2 Diabetes Mellitus1 trial
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Unknown status·—·Phase 3·NCT01137695·40 enrolled
Infusion1 trial
Continuous Subcutaneous Infusion of Pramlintide and Insulin
Completed·—·Phase 4·NCT00291772·13 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 25, 2007
SYMLIN
NDA NDA021332
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pramlintide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Approved[1]
- Company